“You rarely ever see a flat Kaplan-Meier curve...treatment intensification with 12 cycles of apalutamide plus ADT can become an option for patients with high-risk localized prostate cancer who have undergone an RP,' said Jason Hafron . #pcsm

cancernetwork.com/view/bcr-seen-…

🚨 New podcast alert! See our #ONS24 recap with expert perspectives. Oncology Nursing Society

cancernetwork.com/view/administe…

Nivolumab plus ipilimumab has received Type II variation application validation from the European Medicines Agency as first-line treatment for MSI-H or dMMR metastatic colorectal cancer. #gicsm | EU Medicines Agency

cancernetwork.com/view/nivolumab…

“This is the largest study to look at the state of the science in terms of the use of transplants by racial/ethnic minorities, involving over 145,000 transplants over a 10-year period,' wrote Nandita Khera, MD, MPH. #hematology | Dr. Nandita Khera

cancernetwork.com/view/hct-rates…

The FDA has accepted a BLA for a subcutaneous formulation including nivolumab and hyaluronidase for adult patients with solid tumors. U.S. FDA FDA Oncology

cancernetwork.com/view/fda-accep…

Really enjoyed this discussion with Oncology Brothers regarding practical approaches to the patient with newly diagnosed multiple myeloma. UC San Diego Health Moores Cancer Center CancerNetwork® #mmsm

Interested in learning about current treatment options for patients with newly diagnosed multiple myeloma? Watch the next Treatment Algorithm episode with Oncology Brothers and Caitlin Costello, MD 🔽

cancernetwork.com/treatment-algo…

Treatment with cretostimogene grenadenorepvec appears tolerable among patients with high-risk BCG–unresponsive NMIBC in the phase 3 BOND-003 trial. #blcsm #AUA24 | Amer. Urol. Assn. Mark Tyson

cancernetwork.com/view/novel-onc…

Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression. #lcsm | Joshua Sabari, MD

cancernetwork.com/view/mariposa-…

Inequities in access to high-quality care have influenced persistent racial and ethnic disparities in health-related outcomes across the United States. #disparities #healthequity #MedTwitter

cancernetwork.com/view/data-high…

“These findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate-and high-risk tumors,” Nikhile Mookerji, MD. #pcsm #AUA24 | Amer. Urol. Assn. Nik Mookerji

cancernetwork.com/view/18f-psma-…

Administering high-intensity focused ultrasound produced noninferior salvage treatment-free survival outcomes compared with radical prostatectomy in patients with localized prostate cancer. #pcsm #AUA24 | Amer. Urol. Assn.

cancernetwork.com/view/hifu-yiel…

Combining acalabrutinib with bendamustine and rituximab elicited a clinically meaningful and statistically significant PFS improvement over standard of care in adult patients with previously untreated MCL. #lymsm | Michael Wang, MD

cancernetwork.com/view/acalabrut…

Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy. #lcsm | Joshua Sabari, MD

cancernetwork.com/view/flaura2-o…

View our top 5 articles of the week:JTCancerCenter
U.S. FDA FDA Oncology
Omid Hamid MD Toshi Iwase, MD, PhD
1. cancernetwork.com/view/laparosco…

2. cancernetwork.com/view/fda-appro…

3. cancernetwork.com/view/addressin…

4. cancernetwork.com/view/tumor-inf…

5. cancernetwork.com/view/pembroliz…

Nitin Jain, MD, presents data on the efficacy of various chronic lymphocytic leukemia treatments with the Oncology Brothers. #leusm

cancernetwork.com/view/personali…

Alexander Spira, MD, PhD, FACP, presents a case of a 45-year-old male with stage IV NSCLC, bone and liver metastases, and an EGFR exon 20 insertion. #lcsm | Alex Spira, M.D.

cancernetwork.com/view/patient-c…

The panelists explore the importance of communicating with patients, nurses, and caregivers about potential AEs and injection site reactions. #lcsm | Alex Spira, M.D. Sandip Patel MD Dr. Estela Rodriguez Christine Bestvina

cancernetwork.com/view/counselin…

Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients. #mmsm #ONS24 | Oncology Nursing Society

cancernetwork.com/view/outpatien…

In the phase 2 DESTINY-Lung01 trial, trastuzumab deruxtecan showed tolerable anti-tumor activity in patients with HER2-overexpressing or HER2-mutant unresectable or metastatic non–small cell lung cancer. #NSCLC

cancernetwork.com/view/t-dxd-yie…